Industry News for Therapists: September 2025 Updates
Your monthly roundup of what’s new in the therapy world. Quick, clear updates to keep you informed without the overwhelm.
I am so excited to bring you a monthly collaboration, with The Hemingway Report, founded by Steve Duke. Steve writes about the latest mental health industry updates. I like to keep up to date on industry news, as it helps me navigate the therapy business world and stabilise my career for the future. But it’s hard to even know where to look sometimes! So, I thought the between sessions community would benefit from this too.
Steve has kindly agreed for me to share his updates with you here monthly. Please note I have selected updates I think relevant to our community, and his list is much much bigger and comprehensive. Do check out the Hemingway Report for further updates!
I hope you enjoy! These updates will come monthly.
Sophia (Between Sessions Founder) x
I always welcome feedback, do drop me an email at hello@betweensessions.org for any feedback or questions!
September Mental Health Industry Updates 2025
➡️ UK-based HelloSelf launched Companion, an AI tool designed for clients to use between sessions. We’ll be covering this in greater detail soon.
➡️ Seven Starling raised $8M to expand their virtual women’s behavioural health platform across the US.
➡️ The Royal College of Psychiatrists in the UK published a position statement concluding there is limited high-quality evidence for psychedelics’ efficacy and calling for further research.
➡️ Headway announced the expansion of its Electronic Health Record into a “fully connected, insurance-native platform for mental health”. This will provide their 60,000+ providers with AI-assisted notes, integrated telehealth, and simplified billing.
➡️ California passed landmark AI chatbot safeguards (SB 243), implementing new protections for vulnerable users, especially minors, from harm caused by unregulated chatbots.
➡️ New research from Pew found that 46% of Americans believe AI should play a role in providing mental health support to people.
➡️ The FDA published Lykos Therapeutics‘ Complete Response Letter rejecting their MDMA for PTSD application. They cited concerns regarding the reliability of the safety data as the lack of durability of the treatment as the reasons for their rejection.
➡️ London headquartered Unmind, who also provide free access to their app for NHS staff, secured an additional $26M in growth capital from Trinity Capital. This comes just after their $35M raise that was announced in July of this year.